> **HISTORICAL DEVELOPMENT SNAPSHOT**
>
> This document records an earlier MedSenseAI engineering stage.
> Some implementation-status, database, runtime-port, or feature-completion statements below are intentionally preserved as historical evidence and may no longer describe the integrated application.
>
> For the current system state, use the repository root `README.md`, `CURRENT_SYSTEM_STATUS.md`, and `ai_service/README.md`.
# MedSenseAI Complete Repository-Wide Audit

**Audit date:** 2026-08-30

**Repository snapshot:** `main` at `fb29fc88ee9c5a94e4892dd0d8d2d13f8efbfac2`

**Audit mode:** strict evidence-based, repository-wide, read-only except for this report

**Safety boundary:** engineering evidence is not clinical validation; unknown or absent data is never treated as safe

## 1. Executive Summary

MedSenseAI is a strong, unusually careful **medical-data and synthetic DDI engineering foundation**, but it is not yet a complete pharmacy application and is not clinically deployable. Its best-developed areas are typed provenance models, deterministic RxNorm CPC ingestion, synthetic Pakistan-product mapping contracts, provider-neutral DDI contracts, fail-closed adapter mechanics, and a thoroughly tested non-clinical orchestration service.

The repository has a real, locally validated RxNorm CPC identity dataset. That evidence counts for identity normalization and ingestion infrastructure only. It does not provide Pakistani medicine products, a real product-to-ingredient catalog, DDI assertions, clinical recommendations, or pharmacy safety coverage. The real validation database contains 5,839 ingredients and 8,312 aliases, but exactly zero medicine products, product ingredients, and interaction records.

The DDI pathway is real software operating only on synthetic fixtures and neutral contracts. No licensed DDI provider, vendor adapter, authorized clinical dataset, Pakistan coverage study, clinical interpretation layer, or DDI API endpoint exists. Passing synthetic tests therefore earns engineering credit but no real-clinical-data credit.

Several advertised product areas are empty: recommendation engine, lead scoring, sales analytics, OCR, and chatbot. There is no ML/LLM model, training pipeline, dataset, evaluation suite, inference service, or model monitoring. Those features receive no completion credit beyond minimal package/architecture placeholders.

Final scores:

| Measure | Score | Interpretation |
|---|---:|---|
| Overall AI engineering completion | **52%** | Solid foundations and synthetic DDI engineering, but major end-user and real-data features are absent. |
| FYP/demo readiness | **61%** | Good library/CLI demonstration material; no integrated product/DDI API or user interface. |
| Production pharmacy readiness | **9%** | Safety architecture exists, but every decisive clinical, legal, security, integration, and operating gate remains closed. |

## 2. Completion Dashboard

| Area | Completion | Evidence-based status |
|---|---:|---|
| Service foundation | 83% | Starts cleanly, typed settings, database lifecycle, health endpoint, tests. |
| Database and provenance | 75% | 11 constrained tables and auditable ingestion chain; no migrations or production DB proof. |
| RxNorm CPC ingestion | 90% | Real pinned release imported and validated; intentionally narrow identity scope. |
| Canonical identity/normalization | 80% | Deterministic IN/SU handling and conflict quarantine; not a full substance graph. |
| Pakistan product contracts | 67% | Strong immutable DTOs; only synthetic records and no persistence/API. |
| Product eligibility/pair preparation | 71% | Deterministic and fail-closed; synthetic only and not integrated. |
| Salt/substance normalization | 48% | Explicit relationship contract and tests; no real source relationships or ingestion. |
| DDI provider contracts | 72% | Rich source-preserving typed boundary; no licensed implementation. |
| Adapter conformance/governance | 71% | Strong synthetic harness and approval DTOs; not enforced as a mandatory runtime gateway. |
| Synthetic DDI provider | 76% | Complete test double only; zero clinical credit. |
| DDI orchestration | 75% | Deterministic, fail-closed, thoroughly tested; library-only and synthetic. |
| Real DDI capability | 17% | Architecture and procurement documentation only. |
| Feature API/integration | 33% | Only health is exposed; no ingestion, product, DDI, recommendation, or analytics endpoints. |
| Recommendation engine | 5% | Empty package plus architectural intent. |
| Lead scoring | 4% | Empty package. |
| Sales analytics | 4% | Empty package. |
| OCR | 0% | No package, contracts, model, data, tests, or endpoint. |
| Chatbot | 0% | No package, prompt/policy layer, retrieval, model, tests, or endpoint. |
| Security/production operations | 23% | Safe defaults and secret-free contracts, but no production security/operations layer. |
| Deployment/CI | 10% | Packaging exists; no CI, migration workflow, container, deployment, monitoring, or rollback artifacts. |

## 3. Percentage Methodology

Each module was scored with the original fixed weights:

| Category | Weight | Credit rule |
|---|---:|---|
| Architecture | 15% | Coherent design, correct boundaries, dependency separation, safety model. |
| Implementation | 25% | Working executable behavior, not names, empty packages, or contracts alone. |
| Validation | 15% | Input/output checks, failure handling, provenance, deterministic invariants. |
| Testing | 15% | Relevant automated tests and observed passing execution. |
| Real data/provider | 15% | Authorized real data or provider evidence for that exact module. Synthetic data earns 0 here. |
| Integration | 10% | Persistence, API, workflow, or end-user connection appropriate to the module. |
| Documentation | 5% | Accurate, current, operationally useful documentation. |

If real data/provider is genuinely not applicable to a generic infrastructure module, that 15% is excluded and the remaining 85% is proportionally rescaled. It is not marked N/A for features whose purpose requires real data. Passing tests can raise only the testing and validation components; it cannot substitute for implementation, real data, integration, licensing, or clinical validation.

The overall engineering score is a scope-weighted portfolio score. Weights emphasize RxNorm, Pakistan product identity, real DDI, orchestration, database, and integration rather than averaging tiny placeholder packages equally.

| Module | Portfolio weight | Arch. | Impl. | Valid. | Tests | Real | Integr. | Docs | Final |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Service foundation | 5% | 90 | 85 | 85 | 80 | N/A | 70 | 75 | **83%** |
| Configuration/logging | 2% | 80 | 75 | 70 | 55 | N/A | 50 | 60 | **68%** |
| Database/provenance | 7% | 90 | 80 | 75 | 80 | 60 | 50 | 80 | **75%** |
| Ingestion framework/CLI | 3% | 85 | 80 | 75 | 75 | 70 | 60 | 85 | **76%** |
| RxNorm CPC ingestion | 9% | 95 | 90 | 95 | 95 | 95 | 55 | 95 | **90%** |
| Identity normalization | 4% | 85 | 80 | 90 | 85 | 80 | 45 | 85 | **80%** |
| Product mapping contracts | 4% | 90 | 75 | 80 | 90 | 5 | 35 | 90 | **67%** |
| Product eligibility/pairs | 4% | 90 | 85 | 85 | 95 | 0 | 45 | 90 | **71%** |
| Pakistan real product data | 7% | 80 | 10 | 5 | 5 | 0 | 0 | 90 | **21%** |
| Salt/substance normalization | 3% | 80 | 45 | 45 | 80 | 0 | 20 | 75 | **48%** |
| DDI provider contracts | 5% | 95 | 85 | 85 | 95 | 0 | 45 | 95 | **72%** |
| Adapter/conformance/governance | 5% | 95 | 80 | 85 | 95 | 0 | 45 | 95 | **71%** |
| Synthetic DDI provider | 2% | 85 | 95 | 90 | 100 | 0 | 70 | 85 | **76%** |
| DDI orchestration | 7% | 95 | 90 | 90 | 95 | 0 | 55 | 95 | **75%** |
| Real DDI provider/data | 10% | 80 | 0 | 0 | 0 | 0 | 0 | 90 | **17%** |
| Feature API/integration | 5% | 75 | 15 | 25 | 40 | N/A | 10 | 50 | **33%** |
| Recommendation engine | 3% | 30 | 0 | 0 | 0 | 0 | 0 | 10 | **5%** |
| Lead scoring | 2% | 20 | 0 | 0 | 0 | N/A | 0 | 5 | **4%** |
| Sales analytics | 2% | 20 | 0 | 0 | 0 | N/A | 0 | 5 | **4%** |
| OCR | 2% | 0 | 0 | 0 | 0 | N/A | 0 | 0 | **0%** |
| Chatbot | 2% | 0 | 0 | 0 | 0 | N/A | 0 | 0 | **0%** |
| Security/production operations | 4% | 50 | 20 | 20 | 10 | N/A | 10 | 35 | **23%** |
| Deployment/CI | 3% | 40 | 5 | 0 | 0 | N/A | 0 | 25 | **10%** |

Weighted result: `5157 / 100 = 51.57%`, rounded to **52%**.

FYP/demo readiness is separately weighted around demonstrability: service/runtime 10%, real identity ingestion 15%, synthetic product mapping 15%, synthetic DDI 20%, end-user/API integration 20%, tests/reproducibility 10%, and other headline features 10%. This yields **61%**. Production readiness is hard-gated: the absence of both an authorized Pakistan product source and a licensed/accepted DDI provider caps the result below 10%; the surviving safety-architecture and basic runtime credit yields **9%**.

## 4. Repository Statistics

| Statistic | Result |
|---|---:|
| Tracked/relevant project files inspected before this report | **71** |
| Python source modules | **37 files / 6,973 lines** |
| Python test code | **16 files / 5,300 lines** |
| Test fixture data files | **1** |
| Documentation under `docs/` | **12 files / 2,725 lines** |
| All Markdown before this report | **14 files / 2,812 lines** |
| Configuration/build files | **3 files / 80 lines** |
| Collected pytest cases | **217** |
| Database tables | **11** |
| OpenAPI application paths | **1** |
| Real RxNorm archive size | **74,563,744 bytes** |
| Extracted real `RXNCONSO.RRF` size | **30,562,330 bytes** |

Ignored local validation artifacts were inspected at metadata and database level because they are material evidence, but they are not counted as tracked project files. Generated caches, the virtual environment, and Git internals were excluded from source-file inspection.

## 5. Complete Module Inventory

| Module/package | Present behavior | Maturity classification | Primary dependency/consumer |
|---|---|---|---|
| `medsense_ai.main` | FastAPI factory, lifespan, schema creation/disposal | Implemented/tested; development-grade | API/runtime |
| `config` | Typed environment settings | Implemented/tested | All runtime code |
| `logging_config` | Standard console logging | Implemented; basic | Runtime/importer/providers |
| `database` | SQLAlchemy engine, FK pragma, sessions, health, `create_all` | Implemented/tested; no migrations | Domain/ingestion/API |
| `domain` | 11-table medical identity/provenance schema | Implemented/tested; partially superseded by richer DTOs | RxNorm importer |
| `medical_data_ingestion.contracts` | Generic staged-ingestion DTO/protocol | Contract only | Future adapters |
| `medical_data_ingestion.rxnorm_cpc` | Deterministic real CPC IN/SU importer | Implemented, tested, real-data validated | Identity database |
| `medical_data_ingestion.cli` | Local administrative RxNorm command | Implemented/tested | Operator |
| `product_mapping.contracts` | Synthetic Pakistan product, component, relationship, crosswalk DTOs | Implemented contract; no real data/persistence | Preparation/orchestration |
| `product_mapping.preparation` | Eligibility and Cartesian pair expansion | Implemented/tested; synthetic | Orchestration |
| `ddi_providers.contracts` | Neutral provider mappings, lookups, assertions, failures | Implemented contract; no provider | Adapter/orchestration |
| `ddi_providers.adapter` | Base adapter and fail-closed pair/batch wrappers | Implemented/tested; no vendor subclass | Future provider adapters |
| `ddi_providers.conformance` | 26-requirement reusable harness | Implemented/tested synthetically | Future provider acceptance |
| `ddi_providers.governance` | Config, retry classification, lifecycle approval decision | Implemented/tested; not wired into orchestration | Future production control plane |
| `interaction_engine.contracts` | Immutable orchestration request/result graph | Implemented/tested; non-clinical | Service/tests |
| `interaction_engine.service` | Product-to-provider orchestration | Implemented/tested; synthetic only | Library callers only |
| `api` / `schemas` | Health route and health response | Implemented/tested; minimal | Service operators |
| `services` | No behavior | Empty skeleton | None |
| `utilities` | No behavior | Empty skeleton | None |
| `recommendation_engine` | No behavior | Empty skeleton | None |
| `lead_scoring` | No behavior | Empty skeleton | None |
| `sales_analytics` | No behavior | Empty skeleton | None |
| OCR | No package | Absent | None |
| Chatbot | No package | Absent | None |

## 6. File-by-File Audit

Classification legend: **A** complete foundation, **B** implemented and tested, **C** implemented but needs real data/provider, **D** partial, **E** contract/skeleton, **F** documentation, **G** synthetic/test-only, **H** stale/unused, **I** not production-ready.

### Root and documentation files

| File | Class | Audit finding |
|---|---|---|
| `.env.example` | A, I | Safe secret-free local template; lacks production security/provider settings by design. |
| `.gitignore` | A | Excludes environments, databases, source data, logs, and caches; real validation evidence remains local/ignored. |
| `AGENTS.md` | A | Strong safety and engineering rules; audit found implementation largely respects them. |
| `README.md` | F, H | Good setup and identity-only warning; opening claim that interaction handling is unimplemented is stale relative to synthetic orchestration. |
| `pyproject.toml` | A, I | Lean typed dependency ranges and test configuration; no lockfile, production database driver, lint/type/coverage tooling, or vulnerability workflow. |
| `docs/architecture.md` | F | Best current architecture summary; correctly labels synthetic orchestration and deferred production work. |
| `docs/ddi-adapter-conformance.md` | F | Accurate provider adapter, conformance, logging, and lifecycle boundaries. |
| `docs/ddi-development-data-decision.md` | F | Correctly denies public dataset integration and permits synthetic provider work only. |
| `docs/ddi-orchestration-engine.md` | F | Accurate current description of non-clinical orchestration and deferred interpretation. |
| `docs/ddi-provider-acceptance-spec.md` | F | Detailed hard-gate procurement/clinical/technical specification; no provider has passed it. |
| `docs/ddi-source-decision.md` | F, H | Strong research decision, but its final “do not implement engine” next step is historical and now superseded by later synthetic-only decisions. |
| `docs/medical-data-foundation.md` | F, H | Good schema description; statement that the engine is not implemented is stale for the synthetic orchestrator. |
| `docs/medical-data-source-evaluation.md` | F | Comprehensive source evaluation; conclusions remain consistent with current absence of real DDI/Pakistan data. |
| `docs/pakistan-medicine-data-decision.md` | F | Correct conditional-go decision and explicit synthetic-only product boundary. |
| `docs/pakistan-product-mapping-contract.md` | F | Accurate product contract/preparation guide; “future provider” means no real provider, but could be clearer now that synthetic orchestration exists. |
| `docs/rxnorm-cpc-ingestion.md` | F | Accurate importer scope, concurrency limitation, and operating contract. |
| `docs/rxnorm-cpc-real-validation.md` | F, H | Valuable real-data evidence; recorded 62-test/27-import snapshot is obsolete after repository growth. |

### Source files

| File | Class | Audit finding |
|---|---|---|
| `src/medsense_ai/__init__.py` | A | Package/version marker only. |
| `src/medsense_ai/api/__init__.py` | E | Package marker. |
| `src/medsense_ai/api/router.py` | D | Registers only health; no feature routes. |
| `src/medsense_ai/api/routes/__init__.py` | E | Package marker. |
| `src/medsense_ai/api/routes/health.py` | B | Typed 200/503 database health behavior, directly tested. |
| `src/medsense_ai/config.py` | B, I | Validated settings and cache; no production hardening or provider/secret boundary. |
| `src/medsense_ai/database/__init__.py` | A | Clean database exports. |
| `src/medsense_ai/database/base.py` | A | Portable SQLAlchemy declarative base. |
| `src/medsense_ai/database/runtime.py` | B, I | Transaction rollback logging, SQLite FK enforcement, health/disposal; `create_all` and single-process assumptions are not production migration strategy. |
| `src/medsense_ai/ddi_providers/__init__.py` | A, C | Coherent public exports for provider-neutral layer. |
| `src/medsense_ai/ddi_providers/adapter.py` | B, C | Strong fail-closed pair/batch mechanics and sanitized exception handling; no vendor transport implementation. |
| `src/medsense_ai/ddi_providers/conformance.py` | B, C | Reusable 26-check engineering harness; synthetic pass cannot establish clinical validity. |
| `src/medsense_ai/ddi_providers/contracts.py` | B, C | Rich immutable DTOs, strict provenance/capability/coverage validation; no provider data. |
| `src/medsense_ai/ddi_providers/governance.py` | B, C, I | Correct independent approval gates; production decision is not a mandatory precondition in `orchestrate_ddi`. |
| `src/medsense_ai/domain/__init__.py` | A | Domain enum exports only. |
| `src/medsense_ai/domain/enums.py` | B, H | Typed states; interaction enum docstring incorrectly says no engine exists and omits provider-unavailable vocabulary used in newer contracts. |
| `src/medsense_ai/domain/models.py` | B, D, I | Constrained 11-table foundation; product and interaction persistence cannot represent the full newer DTO/provenance contracts. |
| `src/medsense_ai/interaction_engine/__init__.py` | A, C | Clean exports for non-clinical engine. |
| `src/medsense_ai/interaction_engine/contracts.py` | B, C | Strong immutable aggregate/pair invariants and count conservation. |
| `src/medsense_ai/interaction_engine/service.py` | B, C, I | Deterministic fail-closed orchestration; no production activation enforcement, persistence, real provider, or API. |
| `src/medsense_ai/lead_scoring/__init__.py` | E, I | Empty package; no implementation. |
| `src/medsense_ai/logging_config.py` | B, I | Standard structured-enough console format; no request correlation, redaction framework, audit sink, or production log policy. |
| `src/medsense_ai/main.py` | B, I | Clean app/lifespan; startup creates schema directly and exposes default API docs. |
| `src/medsense_ai/medical_data_ingestion/__init__.py` | A | Appropriate public ingestion exports. |
| `src/medsense_ai/medical_data_ingestion/cli.py` | B | Explicit local path/release/checksum administrative command with structured result. |
| `src/medsense_ai/medical_data_ingestion/contracts.py` | E | Useful generic DTO/protocol, but not the actual full RxNorm implementation interface. |
| `src/medsense_ai/medical_data_ingestion/normalization.py` | B | Deterministic Unicode/case/whitespace normalization only; correctly makes no mapping claim. |
| `src/medsense_ai/medical_data_ingestion/rxnorm_cpc.py` | B, I | Robust real importer; caller-supplied checksum is sufficient to mark rows `verified`, so source authenticity is not independently established by code. Single-writer limitation remains. |
| `src/medsense_ai/product_mapping/__init__.py` | A, C | Clean product-mapping exports. |
| `src/medsense_ai/product_mapping/contracts.py` | B, C | Detailed immutable synthetic product/substance/crosswalk contracts; no database mapping or real source. |
| `src/medsense_ai/product_mapping/preparation.py` | B, C | Correct eligibility, deduplication, overlap, and Cartesian pair logic; library-only. |
| `src/medsense_ai/recommendation_engine/__init__.py` | E, I | Empty package; no recommendation behavior. |
| `src/medsense_ai/sales_analytics/__init__.py` | E, I | Empty package; no analytics behavior. |
| `src/medsense_ai/schemas/__init__.py` | E | Package marker. |
| `src/medsense_ai/schemas/health.py` | B | Strict typed health response. |
| `src/medsense_ai/services/__init__.py` | E | Empty shared-service package. |
| `src/medsense_ai/utilities/__init__.py` | E | Empty utilities package. |

### Test and fixture files

| File | Class | Audit finding |
|---|---|---|
| `tests/conftest.py` | G | Isolated temporary SQLite app fixture. |
| `tests/fixtures/rxnorm_cpc/RXNCONSO.RRF` | G | Three-row unmistakably synthetic structural fixture, not medical data. |
| `tests/interaction_engine_fixtures.py` | G | Synthetic requests/crosswalks and mapping-state adapters. |
| `tests/product_mapping_fixtures.py` | G | Fictional Pakistan-context product/ingredient fixtures with allowlist controls. |
| `tests/synthetic_ddi_provider.py` | G | Comprehensive provider test double; deliberately no real medical assertions. |
| `tests/test_config.py` | B, G | 2 tests for defaults and API-prefix validation. |
| `tests/test_database.py` | B, G | 1 direct database health test. |
| `tests/test_ddi_adapter_conformance.py` | B, G | 22 collected cases for conformance, governance, batching, sanitization, immutability, and secret rejection. |
| `tests/test_ddi_provider_contracts.py` | B, G | 33 cases for status semantics, provenance, mapping, failures, batches, and DTO strictness. |
| `tests/test_health.py` | B, G | 2 endpoint cases for healthy and fail-closed unhealthy responses. |
| `tests/test_ingestion_contracts.py` | B, G | 4 generic ingestion/normalization/status-contract cases. |
| `tests/test_interaction_engine.py` | B, G | 73 cases covering mapping/product gates, failures, batches, provenance, determinism, and aggregate invariants. |
| `tests/test_medical_data_models.py` | B, G | 12 schema/provenance/constraint/foreign-key cases. |
| `tests/test_product_mapping_contracts.py` | B, G | 6 immutable contract and synthetic-fixture cases. |
| `tests/test_product_mapping_preparation.py` | B, G | 15 eligibility, combination, overlap, deterministic ordering, and no-clinical-field cases. |
| `tests/test_rxnorm_cpc_ingestion.py` | B, G | 41 importer cases including checksums, idempotency, conflict quarantine, rollback, and malformed inputs. |
| `tests/test_substance_normalization.py` | B, G | 6 explicit relationship and fail-closed salt-normalization cases. |

## 7. AI Feature Audit

No trainable or generative AI exists in the repository. There are no model artifacts, model API integrations, embeddings, vector store, prompt templates, fine-tuning data, training code, evaluation datasets, inference metrics, model cards, bias/error analysis, or drift monitoring. The “AI” work present is deterministic medical-data engineering and a provider-neutral DDI orchestration architecture.

| Feature | Engineering completion | Real-world completion | Evidence |
|---|---:|---:|---|
| DDI orchestration | 75% | 17% | Working synthetic engine; no licensed provider/data, clinical validation, persistence, or endpoint. |
| Pakistan product mapping | 69% synthetic engineering | 5% real-world | Contracts/preparation are tested; no lawful real catalog or pharmacist-reviewed mappings. |
| Recommendation engine | 5% | 0% | Empty package only; no rules, sources, model, evaluation, or API. |
| Lead scoring | 4% | 0% | Empty package; no data schema, labels, model, features, evaluation, or endpoint. |
| Sales analytics | 4% | 0% | Empty package; no queries, metrics, forecasting/optimization, tests, or endpoint. |
| OCR | 0% | 0% | Entirely absent. |
| Chatbot | 0% | 0% | Entirely absent. |
| ML/LLM platform capability | 0% | 0% | No model/data/training/evaluation/inference stack. |

The synthetic DDI path should be described as deterministic orchestration, not a clinically intelligent interaction checker. It preserves source results but does not reason about severity, contraindications, recommendations, dosage, or patient context.

## 8. Medical/Data Source Audit

### Real RxNorm evidence

- Officially sourced pinned CPC release: `2026-08-03`.
- Archive: 74,563,744 bytes; SHA-256 `ca90484736109dc1551dfdca3b4b9831fabdf8664a16dbbe7d8183e222d71000`.
- Extracted `RXNCONSO.RRF`: 30,562,330 bytes; SHA-256 `60302315447ddf1411836c4a88c1a6e16fa8e25fcf508b0a9393fca984e3a87a`.
- First run: 246,041 extracted/validated; 17,190 normalized candidates; 14,151 persisted assertions; 3,039 quarantined; 228,851 ignored out of scope.
- Persisted identities: 5,839 canonical `RXNORM/IN` ingredients and 8,312 `MTHSPL/SU` aliases.
- Repeated run is idempotent at identity/assertion level; validation database has two completed batches and 6,078 quarantine records because quarantine evidence is retained per batch.
- Validation DB: `foreign_key_check=[]`, `integrity_check=ok`.

### Scope and gaps

The importer excludes PIN, MIN, relationships, products, dose forms, strengths, NDCs, weekly deltas, and all DDI content. Consequently it cannot perform real salt-to-moiety normalization, combination decomposition, Pakistan product resolution, or interaction checking.

No authorized real Pakistan product master exists. DRAP public search data is not approved for scraping or production reuse, and no commercial Pakistan feed has been procured. No licensed commercial DDI source or permitted DDInter development dataset has been integrated. No data source in the repository supports clinical recommendation, dosage, contraindication, or patient-specific reasoning.

One integrity terminology risk remains: the importer sets `VerificationStatus.VERIFIED` whenever an expected checksum is supplied and matches. The code does not prove that the supplied checksum came from an official signed/controlled manifest. Integrity verification and source-authority/clinical verification should remain distinct concepts.

## 9. Database Audit

Schema creation produced exactly 11 tables: `data_sources`, `source_releases`, `ingestion_batches`, `provenance_records`, `quarantined_records`, `active_ingredients`, `ingredient_aliases`, `medicine_products`, `product_ingredients`, `external_identifiers`, and `interaction_records`.

Strengths:

- SQLite foreign keys are enabled on every connection; the probe reported zero violations.
- All medical assertions link through provenance to batch, source release, and data source.
- String-backed enums and check constraints preserve portability.
- Canonical pair ordering prevents self/reversed interaction records.
- Mapping state, transformed-record metadata, terminal batch timestamps, record identity, and nonblank values have database constraints.
- Importer transactions roll back and log failures rather than swallowing them.

Blocking limitations:

- Schema management uses `Base.metadata.create_all`; there is no Alembic or other migration/version/rollback workflow.
- No PostgreSQL driver, configuration validation, or PostgreSQL test run exists.
- RxNorm import is explicitly single-writer; there is no cross-process locking or database uniqueness constraint that safely serializes new RXCUI identity creation.
- The persisted `MedicineProduct`/`ProductIngredient` schema is much thinner than `PakistanMedicineProduct`/`ProductComponent`: it lacks component role, complete composition status, salt/form, strength basis, mapping candidates, review evidence, lifecycle, registration evidence, and DDI eligibility.
- `InteractionRecord` cannot faithfully persist the current provider assertion DTO: provider/version/release/interaction ID, endpoint mappings, native classification code/label split, effect, management, evidence class, directionality, contexts, group expansion, references, coverage, use restrictions, and lookup outcome are absent.
- Product crosswalks, substance relationships, provider mappings, approval gates, conformance reports, orchestration requests/results, and operational audit events are not persisted.
- No backup/restore, retention, partitioning, archival, disaster recovery, encryption, row-level access, or tenancy design exists.

## 10. API Audit

The application starts successfully using a temporary SQLite database. Startup schema initialization and shutdown disposal complete, and `GET /api/v1/health` returns HTTP 200 with `{"status":"healthy","database":"available"}`. The endpoint has a typed 503 failure response and is tested.

OpenAPI contains exactly one application path:

| Method | Path | Purpose | Production assessment |
|---|---|---|---|
| GET | `/api/v1/health` | Database availability | Implemented/tested; operational only. |

There are no API endpoints for source/release inspection, RxNorm ingestion, ingredient search, product ingestion/review, product eligibility, DDI orchestration, provider health/governance, interaction history, recommendations, sales analytics, lead scoring, OCR, chatbot, or audit retrieval. Thus working library services do not yet constitute feature integration.

No authentication, authorization, tenant boundary, rate limiting, security headers, trusted-host policy, CORS policy, request/audit correlation middleware, API error envelope, pagination, idempotency key, or production docs-disable policy exists. Swagger/OpenAPI/ReDoc routes are enabled by default.

## 11. Test Audit

### Executed results

| Verification | Result |
|---|---|
| Exact collection | **217 tests collected** |
| Full suite | **217 passed, 0 failed, 0 skipped in 12.54s** |
| Foundation targeted suite | **21 passed in 3.24s** |
| RxNorm targeted suite | **41 passed in 8.40s** |
| Product mapping targeted suite | **27 passed in 0.11s** |
| DDI provider/conformance targeted suite | **55 passed in 0.19s** |
| DDI orchestration targeted suite | **73 passed in 0.28s** |
| Package source compilation | **37/37 modules compiled in memory** |
| Package imports | **37/37 modules imported** |
| `pip check` | **Pass: no broken requirements** |
| `git diff --check` | **Pass** |
| Startup/health probe | **Pass: HTTP 200** |

Exact collected counts by test file:

| Test file | Cases |
|---|---:|
| `test_config.py` | 2 |
| `test_database.py` | 1 |
| `test_ddi_adapter_conformance.py` | 22 |
| `test_ddi_provider_contracts.py` | 33 |
| `test_health.py` | 2 |
| `test_ingestion_contracts.py` | 4 |
| `test_interaction_engine.py` | 73 |
| `test_medical_data_models.py` | 12 |
| `test_product_mapping_contracts.py` | 6 |
| `test_product_mapping_preparation.py` | 15 |
| `test_rxnorm_cpc_ingestion.py` | 41 |
| `test_substance_normalization.py` | 6 |
| **Total** | **217** |

Coverage is deep for the implemented deterministic core: state invariants, input rejection, source provenance, immutable DTOs, batch correlation, malformed provider responses, rollback, quarantine, idempotency, mapping ambiguity, overlap handling, sanitized logging, and “no assertion is not safe” semantics.

Test gaps remain substantial for production: there is no measured line/branch coverage, static type check, lint, dependency vulnerability scan, property/fuzz test, concurrency test, PostgreSQL test, migration test, authorization/security test, real provider contract test, licensed real DDI dataset validation, Pakistan product validation, end-to-end feature API test, browser/UI test, load test, chaos/outage test, backup/restore drill, or clinical validation set.

## 12. Real vs Synthetic Matrix

| Capability/artifact | Real | Synthetic | Missing | Correct interpretation |
|---|:---:|:---:|:---:|---|
| RxNorm CPC release/file | Yes | Test fixture also | No | Real identity vocabulary only. |
| RxNorm import database | Yes | Temp DBs in tests | No | Validates ingestion/provenance, not medical safety. |
| Canonical IN identities/aliases | Yes | Yes | No | Real US-centric terminology; not Pakistan products. |
| Salt/PIN/MIN relationships | No | Contract fixtures | Real source missing | Cannot claim real salt normalization. |
| Pakistan medicine products | No | Yes | Real catalog missing | Synthetic contracts only. |
| Product-to-ingredient mappings | No | Yes | Real pharmacist-reviewed mappings missing | No real pharmacy coverage. |
| DDI provider | No | Yes, test double | Licensed adapter missing | Synthetic conformance only. |
| DDI interaction assertions | No | Yes | Clinical dataset missing | No real interactions stored or returned. |
| DDI orchestration software | Executable code | Inputs/results synthetic | Real integration missing | Engineering capability, not clinical checker. |
| Interaction persistence | Schema only | Tests | Real rows and rich provider schema missing | Zero real interaction rows. |
| Recommendation engine | No | No | Entire feature missing | 0% real feature completion. |
| Lead scoring | No | No | Entire feature missing | 0% real feature completion. |
| Sales analytics | No | No | Entire feature missing | 0% real feature completion. |
| OCR | No | No | Entire feature missing | 0%. |
| Chatbot | No | No | Entire feature missing | 0%. |
| ML/LLM model/training/evaluation | No | No | Entire capability missing | No ML completion credit. |

## 13. Production Readiness

Production pharmacy deployment is a **NO-GO**. This is not caused by a failing test; it follows from absent hard prerequisites:

- no authorized, maintained Pakistan product catalog;
- no licensed and clinically accepted DDI provider;
- no real provider adapter or conformance evidence;
- no Pakistan ingredient/provider coverage measurement;
- no pharmacist-reviewed real mappings or clinical validation set;
- no clinical interpretation/alert policy and no recommendation governance;
- no feature API/workflow or pharmacy UI;
- no authentication, authorization, privacy, or audit-control implementation;
- no migration/PostgreSQL/HA/backup/deployment/observability system;
- no operational incident, recall/correction, rollback, or release-governance workflow.

The current application is appropriate for development and controlled FYP demonstration using explicit synthetic content, plus separate demonstration of real RxNorm identity ingestion. It must not be represented as a production DDI checker or pharmacy decision-support system.

## 14. Security & Medical-Safety Audit

### Strengths

- No LLM-generated medical facts, interactions, dosages, contraindications, or recommendations exist.
- Unknown, ambiguous, unavailable, insufficient-coverage, malformed, and no-assertion states are explicit.
- Typed immutable DTOs reject undocumented fields and inconsistent provenance.
- Source-native classification is preserved; no fabricated universal severity exists.
- Exceptions are logged or translated to explicit failures; there is no silent swallow in the reviewed core.
- Provider logs are tested not to expose source payloads or failure messages.
- Secrets are not present in tracked configuration or provider DTOs.
- Production provider approval is modeled as independent technical, licensing, clinical, Pakistan-coverage, and enablement gates.
- Data import has checksum comparison, provenance, quarantine, transactions, idempotency, and file-change detection.

### Risks and missing controls

- `orchestrate_ddi` accepts a provider directly and does not require a passed `ProviderActivationDecision`; production governance is modeled but not structurally enforced at the execution entry point.
- Matching any caller-provided checksum causes imported assertions to be labeled `VERIFIED`; official-source integrity and assertion verification are conflated.
- No authn/authz, role model, least privilege, tenant isolation, audit event system, patient privacy model, consent, retention, or breach response exists.
- No credential retrieval/rotation implementation exists for future providers.
- No security headers, trusted hosts, rate limits, CORS policy, payload-size policy, TLS deployment policy, or docs exposure policy exists.
- No dependency lock, SBOM, secret scan, SAST, vulnerability scan, signed build, or CI gate exists.
- No production database access controls, encryption, backups, restore tests, HA, or disaster recovery exists.
- No clinical reviewer identity authority, two-person mapping approval workflow, correction/recall workflow, or safety incident process is implemented.
- There is no patient-specific context, contraindication, dosage, duplicate-therapy, allergy, pregnancy, renal/hepatic, route, or formulation logic; same-ingredient overlap is intentionally metadata only.
- The old `InteractionRecord` can store partial source text without the full newer provider contract, creating a future traceability mismatch if used prematurely.

## 15. Documentation Drift

| Drift | Severity | Required correction |
|---|---|---|
| `README.md` says interaction handling is not implemented, while synthetic orchestration now exists. | Medium | State “no real/clinical DDI” and link the synthetic engine. |
| `medical-data-foundation.md` says the interaction engine is not implemented. | Medium | Mark statement historical or distinguish old enum from current synthetic engine. |
| `domain/enums.py` repeats the pre-engine statement and lacks the newer provider-unavailable model. | Medium | Clarify legacy persistence vocabulary versus current orchestration DTOs. |
| `ddi-source-decision.md` ends with “do not implement the DDI engine,” superseded by later synthetic-only decisions. | Medium | Add a superseded-by note without weakening the real-data prohibition. |
| `rxnorm-cpc-real-validation.md` records 62 tests and 27 imports from an earlier snapshot. | Low | Label counts as historical and point to current audit. |
| Product, provider, and engine DTOs are richer than the persisted domain schema, but no document owns the reconciliation plan. | High | Add a versioned persistence-gap design before real integration. |
| No single status page distinguishes implemented library behavior, API availability, real-data availability, and production approval. | Medium | Maintain a capability/readiness matrix. |

The core decision documents remain safety-consistent: later work permits synthetic architecture but does not authorize real DDI or pharmacy use. Drift is primarily temporal/status wording, not an observed relaxation of medical-safety rules.

## 16. Git State

Before this report was created:

- Branch: `main`.
- HEAD: `fb29fc88ee9c5a94e4892dd0d8d2d13f8efbfac2`.
- Commit time: `2026-08-30T16:06:05+05:00`.
- Commit subject: `feat: add audited synthetic DDI orchestration engine`.
- `git status --short`: clean.
- `git diff --check`: pass.
- No commit or push was performed.

The only requested post-snapshot repository change is this new uncommitted report, `docs/FULL_PROJECT_AUDIT.md`.

## 17. Blocker Register

| Priority | Blocker | Severity | Exit evidence |
|---:|---|---|---|
| 1 | No licensed, authorized, clinically accepted DDI provider or dataset | Critical | Executed rights, accepted schema/sample, conformance, clinical sign-off, pinned release. |
| 2 | No lawful, current, verified Pakistan product-to-ingredient catalog | Critical | Authorized feed/master, pharmacist review, lifecycle/update contract, measured coverage. |
| 3 | No real provider adapter, crosswalk, empty-result semantics, or Pakistan coverage test | Critical | Provider-specific adapter and all acceptance/conformance gates pass. |
| 4 | No clinical interpretation, alert, recommendation, override, or incident-governance layer | Critical | Approved clinical policy and independently validated implementation. |
| 5 | Product/provider/orchestration contracts are not represented by the persistence schema | High | Migration-backed schema retaining every required source, mapping, outcome, and audit field. |
| 6 | No feature API or integrated user workflow beyond health | High | Authenticated APIs and end-to-end tests for governed use cases. |
| 7 | No authentication, authorization, privacy, audit, or production security controls | Critical | Threat model and tested least-privilege controls with audit retention. |
| 8 | No production database/migration/concurrency/backup/HA path | High | PostgreSQL migration, concurrency, restore, performance, and failure tests. |
| 9 | Recommendation, lead scoring, sales analytics, OCR, and chatbot are absent | High for advertised scope | Approved specifications, data, implementation, evaluation, tests, and integration per feature. |
| 10 | No CI/CD, deployment, observability, vulnerability, or rollback system | High | Reproducible gated pipeline, monitored deployment, rollback and incident runbooks. |
| 11 | Provider lifecycle gate is not mandatory at orchestration entry | High | A single execution boundary that cannot bypass approved activation state. |
| 12 | Caller-provided checksum can confer `VERIFIED` status | High | Separate official artifact integrity, provenance authority, and human/clinical verification states. |
| 13 | No automated real-data regression, PostgreSQL, concurrency, load, or security suite | High | Controlled non-redistributed validation jobs and production-relevant test matrix. |
| 14 | Documentation/status drift can misstate what is implemented | Medium | Updated status matrix and supersession markers. |

## 18. Module Remaining Work

| Module | Required remaining work |
|---|---|
| Foundation | Add production configuration profiles, consistent error/correlation middleware, and release metadata. |
| Database | Design migrations; reconcile DTO persistence; add PostgreSQL, locks, audit events, backups, retention, and restore validation. |
| RxNorm | Separate integrity from verification; automate controlled release manifests; plan retirement/delta/relationship handling only after approval. |
| Identity | Add approved PIN/MIN/relationship/substance sources and conservative reviewed mapping workflows. |
| Pakistan products | Procure lawful source; implement ingestion, persistence, pharmacist review, freshness, corrections, and coverage reporting. |
| Product preparation | Persist eligibility evidence and expose a non-clinical reviewed API/workflow. |
| DDI contracts | Version the contract and map it completely to persistence and API schemas. |
| Provider adapter | Select provider, implement transport/auth/retry/release adapter, and pass licensed conformance scenarios. |
| Provider governance | Store approval evidence and make activation a non-bypassable runtime prerequisite. |
| Orchestration | Add persistence, idempotency, authorization, timeout budgets, audit trace, and governed API; retain non-clinical semantics until approved. |
| Clinical interpretation | Create separate pharmacist-governed design, source rules, validation set, display semantics, overrides, and incident controls. |
| Recommendation | Define permitted recommendation scope and validated deterministic sources before implementation. |
| Lead scoring | Define non-clinical business objective, lawful labeled data, baseline, metrics, bias/error analysis, and monitoring. |
| Sales analytics | Define event/order schema, deterministic KPIs, privacy rules, forecasting/optimization acceptance, and tests. |
| OCR | Define document types, consent/privacy, ground-truth data, extraction uncertainty, human review, and evaluation. |
| Chatbot | Define allowed intents, retrieval sources, refusal/escalation, medical-safety policy, evaluation, and audit before model integration. |
| API | Add only approved endpoints with auth, authorization, idempotency, pagination, validation, and typed error responses. |
| Security/operations | Threat model, secret manager, RBAC, audit logs, security headers, rate limits, scans, monitoring, incident and disaster recovery. |
| Documentation | Correct drift, mark superseded decisions, and maintain one evidence-linked capability/readiness dashboard. |

## 19. Recommended Implementation Roadmap

1. **Freeze the clinical boundary.** Publish the capability/readiness matrix and correct stale wording while retaining the synthetic/real separation.
2. **Resolve source procurement first.** Obtain written Pakistan product rights and begin FDB/Medi-Span/other licensed DDI evaluation under the existing hard-gate specification.
3. **Design the production data model.** Map every product, crosswalk, provider assertion, coverage, use restriction, lookup outcome, approval record, and orchestration trace to a versioned migration plan.
4. **Build the operating foundation.** Add PostgreSQL, migrations, import locking, backups/restores, audit events, controlled secrets, authentication, authorization, and production configuration.
5. **Implement lawful Pakistan product ingestion.** Start with a controlled pharmacy master/schema, source-backed composition, pharmacist review, quarantine, changes, and coverage metrics.
6. **Implement one licensed provider adapter.** Pin versions, preserve native data, prove failure/empty-result semantics, pass all synthetic and authorized conformance scenarios, and measure Pakistan coverage.
7. **Make governance non-bypassable.** Persist lifecycle approvals and require a valid activation decision at the only production orchestration entry point.
8. **Add authenticated feature APIs and a safe FYP mode.** Expose clearly watermarked synthetic product/DDI flows separately from real RxNorm identity administration; add end-to-end tests.
9. **Validate clinical behavior before interpretation.** Build a pharmacist-approved validation set, alert/display rules, overrides, correction/incident handling, and independent acceptance evidence.
10. **Sequence later AI features independently.** Recommendation, lead scoring, sales analytics, OCR, and chatbot each require their own data, safety/privacy scope, baseline, evaluation, monitoring, and API plan; do not treat empty packages as parallel progress.

Recommended near-term FYP deliverable: a visibly non-clinical, synthetic end-to-end demonstration that shows product eligibility, explicit blocked states, pair expansion, provider outcomes, provenance, and “no assertion is unknown” behavior, while separately demonstrating the real RxNorm identity importer. Do not combine the two in a way that implies real interaction coverage.

## 20. Verdict

**Audit verdict: CONDITIONAL PASS for engineering foundation and controlled FYP development; NO-GO for production pharmacy or clinical use.**

The repository demonstrates disciplined deterministic engineering and unusually strong fail-closed synthetic DDI tests. It is not a finished AI pharmacy system. The 52% engineering score reflects substantial implemented infrastructure; the 61% FYP score reflects demonstrable but library-oriented synthetic workflows; the 9% production score reflects that no licensed DDI source, Pakistan catalog, clinical validation, secure workflow, or production operating platform exists.

No observed code path fabricates real interaction facts. That safety property must be preserved while the missing real-source, clinical-governance, persistence, API, security, and operations work is completed.
